John Lambert PhD GAICD
Chief Executive Officer and Managing Director
John has more than 16 years of drug discovery and development experience. His appointments include leadership roles in Drug Development, Operations Management and Drug Discovery (Biota Pharmaceuticals), as Senior Director (Medicines Development for Global Health) and as an academic researcher in medicinal and biological chemistry (University of Melbourne, ANU and Harvard University).
He is an experienced manager of both in early and late development of therapeutics and has built and led multidisciplinary project teams tasked with the objective of delivering clinical proof-of-concept for new products. As such, his experience spans the entire spectrum of drug development from design of development strategy through project management, manufacture, formulation, pre-clinical and clinical development and regulatory affairs.
John joined Amplia Therapeutics as Operations Manager in August 2018 and was appointed as CEO on 24 June 2019 and Managing Director on 6 February 2020.
Mark Devlin B. Sc. (Hons) PhD GradD Drug Dev
Chief Scientific Officer
After obtaining a PhD in Pharmacology from the University of Melbourne, Mark has worked in a variety of roles focused on drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology. Mark worked at the Peter MacCallum Cancer Centre between 2008 and 2018 in a number of roles for the CRC for Cancer Therapeutics (CRC), first as Head of the CRC’s Translational Cancer Biology Laboratory and later as Director of Translational Cancer Biology for the CRC. In his role as a lead scientist, Mark and his team were involved in the PRMT5 program that was licensed by the CRC to MSD, in 2016 and the Chromatin-Modifying Enzyme programs licensed to Pfizer Inc in 2018.
Mark was also the Biology Leader on the CRC Programs that delivered AMP945 and AMP886 that are now being developed by Amplia.
In addition to his scientific experience, Mark has held a number of business-facing roles as COO of the CRC where he led due-diligence activities between the CRC and Pfizer and later as CEO and Managing Director of the commercial partner in the CRC, CTxONE Pty Ltd. Mark is an honorary Associate Professor in the Department of Pharmacology at the University of Melbourne, and has a Graduate Diploma in Drug Development from the University of New South Wales and an MBA from the Melbourne Business School.
Rhiannon Jones BSC (Hons) PhD
Rhiannon has a background in research operations and project management and more than 10 years of experience in the medical research and biotechnology sector. Rhiannon has previous appointments as Director, Operations and Governance (Cancer Therapeutics CRC), Project Manager (WEHI, Business Development Office), Scientific Coordinator (WEHI, Inflammation Division) and a postdoctoral researcher in organic chemistry (Monash University, Chemistry Department). Her experience includes project management, communications, policy development and oversight, ethics committee submissions, risk management and staff professional development systems.
Rhiannon has a PhD in chemistry and a BSc(Hons) from the University of Adelaide and a Certificate in Governance Practice from the Governance Institute of Australia.
Charlotte Mulder BVSc (Hons), MBA
Pincipal Development Manager
Charlotte has over ten years’ experience in drug development. Her early career as a Veterinarian in mixed practice in Australia and the UK was followed by a transition into veterinary clinical development with Pfizer Animal Health, then human drug development. Charlotte worked with Medicines Development for Global Health from 2011 until 2021, most recently in the role of Principal Development Manager and Project Leader. She has worked on a variety of projects at different stages of development, spanning preclinical through to regulatory approval. Her experience includes coordination of cross-functional development teams, stakeholder communication, management of international collaborative relationships, and strategic and technical input into development programs.
Charlotte has a Bachelor of Veterinary Science (Hons) from the University of Melbourne and an MBA from Melbourne Business School.
Chief Financial Officer
Hamish is a Chartered Accountant and director at Bio101 Financial Advisory Pty Ltd, a financial services firm providing outsourced CFO, tax and company secretarial solutions to the life science sector.
Hamish is CFO and/or Company Secretary for numerous ASX listed and unlisted public and private companies. Hamish holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT and a Certificate in Governance Practice from the Governance Institute of Australia.
Hamish has was appointed as Chief Financial Officer of Amplia Therapeutics Limited on 1 October 2021.